Jose Villamarin Corrales (@JoseV_MD) header
Jose Villamarin Corrales (@JoseV_MD) profile picture

Research at @MayoClinic I IM PGY-1 @EinsteinDeptMed |MD’24 @lacentralec🇪🇨 I Tennis 🎾

Joined April 2022
Photo by Jose Villamarin Corrales (@JoseV_MD)Photo by Jose Villamarin Corrales (@JoseV_MD)Photo by Jose Villamarin Corrales (@JoseV_MD)Photo by Jose Villamarin Corrales (@JoseV_MD)Photo by Jose Villamarin Corrales (@JoseV_MD)Photo by Jose Villamarin Corrales (@JoseV_MD)Photo by Jose Villamarin Corrales (@JoseV_MD)
Jose Villamarin Corrales retweeted
A free, useful calculator from @dr_aac and his team at @MayoClinic that predicts the timing of weight regain after stopping semaglutide or tirzepatide, presented today at #ObesityWeek #OW2026 GLP-1 Weight-Regain Risk Calculator: glp1regainrisk.com
9
32
4
96
5,274
Jose Villamarin Corrales retweeted
35% more weight loss than tirzepatide alone and more cardiometabolic benefit, a potential enhancement of menopausal hormone therapy effect. @MayoClinic small retrospective study with matching thelancet.com/journals/lanog…
8
86
9
436
73,990
New op-ed from @PopovVioleta: #MASLD can be prevented by treating obesity, but gaps in Medicaid are preventing access to lifesaving treatment. We need solutions to keep patients healthy. ow.ly/YOYm50WlWmc
2
8
2,032
Jose Villamarin Corrales retweeted
Excited to share our review on Precision Medicine for Obesity treatment! @MayoClinic @MayoClinicGIHep
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
3
5
32
3,879
Jose Villamarin Corrales retweeted
At @DDWMeeting The next fronteir for obesity phenotypes requires to elucidate the unique microbial signature of each phenotype. @danazcomd (rising start) showing the data today. Fascinating findings!
1
7
1
50
5,187
Jose Villamarin Corrales retweeted
Wrapping up #DDW2025 day 4 with two great abstracts from our team. @alexticho showing the conservative expression of #GLP1 in the ileum and colon and ⁦@marantoec⁩ describing weight recurrence after RYGB with a high CTS-GRS. ⁦@MayoClinicGIHep⁩ ⁦@AmerGastroAssn⁩
1
2
1
29
2,991
Jose Villamarin Corrales retweeted
SO grateful to have crossed paths with essential humans on my last day at #DDW2025 🖤📸 Proud of @SucapaAraya ✨who outstandingly presented our #IBD research to many visitors📈🙏🏽 My heart is full ❤️‍🩹 Love this community and LOVE GI #AGAGastroSquad @AmerGastroAssn
6
13
83
4,981
Jose Villamarin Corrales retweeted
Excited to share 24 abstracts, lectures and symposium with two plenaries this week. Thanks to all the amazing collaborators @DDWMeeting @MayoClinicGIHep @AmerGastroAssn @ASGEendoscopy @phenomixscienc1
1
5
15
1,020
Jose Villamarin Corrales retweeted
Celebrating our amazing team! Great year of many accomplishments! This team makes it happen! So proud of everyone! @MayoClinic @MayoClinicGIHep @DDWMeeting
7
52
3,191
Jose Villamarin Corrales retweeted
🚨BREAKING: Semaglutide for MASH: A Step Forward in Metabolic Liver Disease Phase 3 data just released (NEJM 2025): In 800 patients with biopsy-confirmed MASH and fibrosis stage 2–3, semaglutide 2.4 mg weekly delivered impressive results at 72 weeks (compared to placebo): Histologic Outcomes: ✅ 63% achieved resolution of steatohepatitis without worsening fibrosis (vs. 34% placebo) 🔄 37% had fibrosis improvement without worsening steatohepatitis (vs. 22%) 🎯 33% achieved both fibrosis reduction and steatohepatitis resolution (vs. 16%) Metabolic Benefits: ⚖️ –10.5% mean body weight reduction (vs. –2.0%) ⚠️ GI side effects more frequent; pain scores unchanged This reinforces semaglutide’s growing role across the spectrum of metabolic disease—now including MASH. Funded by Novo Nordisk | ClinicalTrials.gov: NCT04822181 nejm.org/doi/full/10.1056/NE… #MASH #NASH #GLP1 #ObesityMedicine #Semaglutide #MetabolicHealth #LiverDisease #Hepatology #NEJM
7
94
8
295
25,169
Jose Villamarin Corrales retweeted
🧬 NEW STUDY: Obesity’s Massive Health Impact--from my research group, led by the brilliant @yao_zhiqi. - - - 🚨 In a nationwide study of 270,000+ adults using the All of Us Research Program, obesity was linked to a higher risk of 16 health conditions—with risk increasing by obesity severity (BMI ≥30). 📊 Top Takeaways • 42.4% of U.S. adults have obesity; 9.8% have class III (BMI ≥40) • Class III obesity was linked to: 🔹 11x higher risk of Obstructive Sleep Apnea 🔹 7.7x higher risk of Type 2 Diabetes 🔹 6.7x higher risk of Fatty Liver Disease 🔹 3.5x higher risk of Heart Failure ❤️‍🩹 51.5% of Obstructive Sleep Apnea cases in the population could be attributed to obesity. Similar trends were seen for T2D, gout, and fatty liver disease (MASLD). 💊 As anti-obesity medications like semaglutide and tirzepatide reshape treatment, understanding obesity’s full burden is crucial for prevention and policy. 🔍 This is one of the largest and most diverse obesity studies ever conducted in the U.S., reinforcing obesity as a root cause—not just a risk factor. 📚 Source: evidence.nejm.org/doi/10.105… #Obesity #PublicHealth #GLP1 #Semaglutide #ObesityCare #AllOfUs #ChronicDisease #HealthcareInnovation Thanks to all the collaborators @CiccaroneCenter @MichaelJBlaha @BevTchangMD @rblument1 @khurramn1
7
55
2
144
12,736
Jose Villamarin Corrales retweeted
🌍 #WorldObesityDay ⭕ is here! Today, we unite to demand systemic change across health, food, and societal systems. Let’s build healthier futures for everyone—together! 👉 Get involved: worldobesityday.org 📺 Watch: youtu.be/Jy2uIgvs7qs?si=XTwI… #WOD2025 #ChangingSystems
2
27
3
48
3,664
Jose Villamarin Corrales retweeted
Excited to have met with colleagues, friends and mentors from the Precision Medicine for Obesity Program @MayoClinicGIHep to observe #WorldObesityDay! @ObesitySociety @WorldObesity @dr_aac @MDanielaHurtado
2
20
1,773
Jose Villamarin Corrales retweeted
🌍 Today is #WorldObesityDay ⭕️! Obesity rates are rising—not because of individual choices, but due to failing systems. It’s time for systemic change in health, food, and societal systems. 📢 Join us in calling for action! 👉 worldobesityday.org #WOD2025 #ChangingSystems
30
4
46
3,398
Jose Villamarin Corrales retweeted
🚨 Thrilled to share that I will be delivering an oral and a poster presentation at #DDW2025 @DDWMeeting Proud of our lab’s efforts that resulted in 2 orals and 9 posters! Beyond grateful for the continuing support! @dr_aac @MDanielaHurtado @MayoClinicGIHep @UTSWIMchief
3
3
49
3,254
Jose Villamarin Corrales retweeted
🚨Thrilled to share our new chapter on the role of precision medicine in obesity management, now part of the SAGES Manual of Metabolic and Bariatric Surgery! Grateful for the opportunity to contribute! @dr_aac @SAGES_Updates @OMGhanemMD link.springer.com/chapter/10…
3
5
35
10,085
Jose Villamarin Corrales retweeted
I am so grateful to have joined my first #WalkToEndAlzh. Doing research on AD, it was incredibly meaningful to walk alongside people with the disease and their families, as well as others dedicated to raising awareness and hope.
1
8
1,602
Jose Villamarin Corrales retweeted
Hi #MedTwitter I am Bruno Velit, a Peruvian IMG 🇵🇪 applying for #InternalMedicine this #Match2025. My interests include health equity and medical education. Excited to connect with programs, peers and mentors!
3
14
63
5,299
Jose Villamarin Corrales retweeted
Hi #Medtwitter! I am Maria Antonia Espinosa, an #IMG from Ecuador 🇪🇨 and currently a Research Fellow at @MayoClinicGIHep. Applying to #InternalMedicine this cycle, #Match2025 Happy to connect!
12
25
4
191
13,350
A wise doctor once asked me, "Do you know where in the US your name is?" At the time, I was confused, but now I understand. My name will be at @TigmerSA_IntMed in Texas! I am so happy, and believe that God's plans are always perfect. Coming back to Texas! @IMG_Ecuador #Match2024
33
15
438
16,554